Population growth and aging, not rising age-standardized rates, drives the increase, with underlying causes varying widely by age and region.
|Articles|February 1, 1996
The American Journal of Managed Care
- February 1996
- Volume 2
- Issue 2
The Economics of Compliance in Managed Healthcare Settings
Advertisement
Articles in this issue
over 30 years ago
Adapting Pharmacy Services to the Needs of Managed Careover 30 years ago
Advanced Practice Nurses and Success of Organized Delivery Systemsover 30 years ago
Ethical Issues in Managed CareAdvertisement
Related to this article
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
The conference, held in New Orleans, Louisiana, by the American Academy of Ophthalmology, will offer 3 full days of content spanning from glaucoma to dry eye.
A JAMA analysis of 2021-2023 death records found heat-related mortality varied sharply by occupation and industry among working-age US adults.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know if Retatrutide Is Classified as a Biologic
2
FDA Approves First Symptomatic Dermographism Treatment
3
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
4
FDA Approves Tucatinib Maintenance for HER2+ Metastatic Breast Cancer
5